Dianthus (DNTH) SVP/General Counsel Adam Veness Exercises Options

What Happened Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics (DNTH), exercised stock options on Aug 13, 2026 to acquire 15,000 shares at an exercise price of $18.17 per share, for a cash cost of $272,550. The filing also reports a simultaneous disposition of a derivative instrument for 15,000 shares at $0, reflecting the conversion/termination of the option instrument upon exercise. No sale of the acquired shares was reported in this Form 4.

Key Details

• Transaction date: 2026-08-13
• Acquired: 15,000 common shares via option exercise at $18.17/share — total cash paid $272,550
• Disposed (derivative): 15,000 units at $0.00 (the option/derivative instrument converted on exercise)
• Shares owned after transaction: not specified in the provided filing details
• Footnote: Shares underlying the option vested 25% on June 20, 2024, with the remaining 75% vesting in equal monthly installments over the next three years, subject to continued service
• Filing timeliness: filed Aug 14, 2026 (no late-filing flag noted in the provided data)

Context This was an option exercise (transaction code M). Because no immediate sale of the acquired shares was reported, the filing indicates ownership was increased rather than a cashless exercise-and-sell. Exercises are routine for option holders when vested and do not by themselves indicate intent to buy or sell in the market, but they do result in insiders holding more stock.